The stock of Sorrento Therapeutics Inc (NASDAQ: SRNE) rose to $9.46 after gaining 6.65%. The company moves into a research collaboration agreement that will rely upon the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology in its undertakings. It collaborates with Mayo Clinic in the deal, hoping to make a breakthrough in the human clinical proof of concept studies. Their activities will be targeting several indications and products.
The functioning of the Sofusa platform
Sofusa can easily be described as a working drug delivery platform that plays a significant role in administering diverse biologic therapies. The administration might take different forms. For example, there happens to be the kind of administration done directly to the lymphatic system.
The other way is the administration through the skin surface. The good thing about therapies administered in the above way is generally how such medications pull along with outstanding effectiveness. For instance, such medications have been rated highly to guarantee safety and efficacy in immuno-oncology therapies.
Delivery to the lymphatics is a targeting strategy that could present several advantages that couldn’t be stipulated in the traditional systematic subcutaneous injections and infusions. The one glaring advantage has to do with how the new strategy facilitates reduced dosing.
One study named MC20711 was the first one to confirm the above assertion. The study specifically incorporated patients struggling with Metastatic Melanoma, and it was to play an investigational role.
It is becoming clearer with more studies that the checkpoint therapies in most cases exhibit outstanding results among patients. The only setback is the point that the response rates continue to relatively lower than expected. Many reasons have been cited to explain the phenomena, one of them being poor exposure to the drug targets. It happens to drug targets residing specifically within the lymph nodes.
Researchers conducting the studies look forward to witnessing a significant spike in clinical response. The other thing the researchers anticipate is a substantial decrease in systemic side effects.